ArticleThe American journal of tropical medicine and hygiene2015
Genome-Scale Protein Microarray Comparison of Human Antibody Responses in Plasmodium vivax Relapse and Reinfection.
Open access · bronzeAbstract readComparative Study
In one paragraph
Article in The American journal of tropical medicine and hygiene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.3field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Antibody profiles to plasmodium merozoite surface protein-1 in Cambodian adults during an active surveillance cohort with nested treatment study.Malaria journal · 2016Trial
- Proteome-wide characterization of Plasmodium vivax antigens using a high-density peptide array.PLoS pathogens · 2026Article
- Analytical approaches for antimalarial antibody responses to confirm historical and recent malaria transmission: an example from the Philippines.The Lancet regional health. Western Pacific · 2023Article
- Malaria Resilience in South America: Epidemiology, Vector Biology, and Immunology Insights from the Amazonian International Center of Excellence in Malaria Research Network in Peru and Brazil.The American journal of tropical medicine and hygiene · 2022Article
- Systems biology of malaria explored with nonhuman primates.Malaria journal · 2022Review
- PvMSP8 as a NovelPathogens (Basel, Switzerland) · 2021Article
- Heterogeneity in response to serological exposure markers of recent Plasmodium vivax infections in contrasting epidemiological contexts.PLoS neglected tropical diseases · 2021Article
- Anti-MSP-10 IgG indicates recent exposure to Plasmodium vivax infection in the Peruvian Amazon.JCI insight · 2020Article
- Evaluation of antibody responses to the early transcribed membrane protein family in Plasmodium vivax.Parasites & vectors · 2019Article
- Evolutionary history of humanProceedings of the National Academy of Sciences of the United States of America · 2018Article
- Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination.Malaria journal · 2018Article
- Advancing Research Models and Technologies to Overcome Biological Barriers to Plasmodium vivax Control.Trends in parasitology · 2018Review
- Identification ofClinical proteomics · 2018Article
- High prevalence of very-low Plasmodium falciparum and Plasmodium vivax parasitaemia carriers in the Peruvian Amazon: insights into local and occupational mobility-related transmission.Malaria journal · 2017Article
- Naturally acquired antibody responses to more than 300 Plasmodium vivax proteins in three geographic regions.PLoS neglected tropical diseases · 2017Article
- Micro-epidemiology and spatial heterogeneity of P. vivax parasitaemia in riverine communities of the Peruvian Amazon: A multilevel analysis.Scientific reports · 2017Article
- Characterization of P. vivax blood stage transcriptomes from field isolates reveals similarities among infections and complex gene isoforms.Scientific reports · 2017Article
- A Plasmodium yoelii HECT-like E3 ubiquitin ligase regulates parasite growth and virulence.Nature communications · 2017Article
- Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.Malaria journal · 2017Article
- Characterizing Antibody Responses to Plasmodium vivax and Plasmodium falciparum Antigens in India Using Genome-Scale Protein Microarrays.PLoS neglected tropical diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 2 countries.
Raul ChuquiyauriDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Douglas M MolinaDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Eli L MossDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Ruobing WangDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Malcolm J GardnerDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Kimberly C BrouwerDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Sonia TorresDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Robert H GilmanDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Alejandro Llanos-CuentasDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Daniel E NeafseyDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Philip FelgnerDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Xiaowu LiangDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Joseph M VinetzDepartment of Medicine, Division of Infectious Diseases, University of California San Diego, La Jolla, California; Laboratorio ICEMR-Amazonia, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú; Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Perú; Antigen Discovery Inc., Irvine, California; Malaria Research Group, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts; Seattle Biomed, Seattle, Washington; Department of Medicine, Division of Global Public Health, University of California San Diego, La Jolla, California; Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland jvinetz@ucsd.edu.
Johns Hopkins University · US
Funding
Sugar-feeding behavior of the malaria vector Nyssorhynchus darlingi and development of effective attractive toxic sugar baits (ATSB) to increase intervention success in PeruU19AI089681 · NIAID · YALE UNIVERSITY · PI CASTRO, MARCIA C. · 2010 to 2023
$20.1MUniversity of California Launching Future Leaders in Global Health Research Training ProgramD43TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIG R COHEN, Sung-Jae Lee · 2017 to 2026
$14.7MTransmissionU19AI089686 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ZIMMERMAN, PETER A. · 2010 to 2016
$9.9MHuman Reservoirs of Plasmodium vivax Transmission in the Peruvian AmazonR01AI067727 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VINETZ, JOSEPH M. · 2006 to 2010
$3.4MTranslational Research Development for Endemic Infectious Diseases of AmazoniaD43TW007120 · FIC · YALE UNIVERSITY · PI VINETZ, JOSEPH M. · 2004 to 2020
$3.0MProtective biomarkers for the development of vaccines against malariaR44AI066791 · NIAID · IMMPORT THERAPEUTICS, INC. · PI FELGNER, PHILIP LOUIS · 2012 to 2014
$2.3MPredicting naturally acquired humoral immunity against malariaR01AI095916 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FELGNER, PHILIP LOUIS · 2012 to 2016
$2.1MPatient-Oriented Research in Tropical Infectious DiseasesK24AI068903 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VINETZ, JOSEPH M. · 2006 to 2015
$1.5MScanning the P. falciparum proteome for vaccine antigensR43AI066791 · NIAID · IMMPORT THERAPEUTICS, INC. · PI FELGNER, PHILIP LOUIS · 2005 to 2006
$599kAntibodies to malaria blood stages in mixed-species infectionsR43AI075692 · NIAID · IMMPORT THERAPEUTICS, INC. · PI LIANG, XIAOWU · 2008 to 2009
$594kFIC NIH HHS D43 TW007120FIC NIH HHS D43TW007120FIC NIH HHS D43 TW009343Medical Research Council MR/K007467/1NIAID NIH HHS AI066791NIAID NIH HHS AI075692NIAID NIH HHS AI089686NIAID NIH HHS AI095916NIAID NIH HHS K24 AI068903NIAID NIH HHS K24AI068903NIAID NIH HHS R01 AI067727NIAID NIH HHS R01AI067727NIAID NIH HHS R01 AI095916NIAID NIH HHS R43 AI066791NIAID NIH HHS R43 AI075692NIAID NIH HHS R44 AI066791NIAID NIH HHS U19 AI089681NIAID NIH HHS U19AI089681NIAID NIH HHS U19 AI089686
Abstract
Large scale antibody responses in Plasmodium vivax malaria remains unexplored in the endemic setting. Protein microarray analysis of asexual-stage P. vivax was used to identify antigens recognized in sera from residents of hypoendemic Peruvian Amazon. Over 24 months, of 106 participants, 91 had two symptomatic P. vivax malaria episodes, 11 had three episodes, 3 had four episodes, and 1 had five episodes. Plasmodium vivax relapse was distinguished from reinfection by a merozoite surface protein-3α restriction fragment length polymorphism polymerase chain reaction (MSP3α PCR-RFLP) assay. Notably, P. vivax reinfection subjects did not have higher reactivity to the entire set of recognized P. vivax blood-stage antigens than relapse subjects, regardless of the number of malaria episodes. The most highly recognized P. vivax proteins were MSP 4, 7, 8, and 10 (PVX_003775, PVX_082650, PVX_097625, and PVX_114145); sexual-stage antigen s16 (PVX_000930); early transcribed membrane protein (PVX_090230); tryptophan-rich antigen (Pv-fam-a) (PVX_092995); apical merozoite antigen 1 (PVX_092275); and proteins of unknown function (PVX_081830, PVX_117680, PVX_118705, PVX_121935, PVX_097730, PVX_110935, PVX_115450, and PVX_082475). Genes encoding reactive proteins exhibited a significant enrichment of non-synonymous nucleotide variation, an observation suggesting immune selection. These data identify candidates for seroepidemiological tools to support malaria elimination efforts in P. vivax-endemic regions.
Indexed as
AdolescentAdultAgedAged, 80 and overAntibodies, ProtozoanAntibody FormationAntigens, ProtozoanChildChild, PreschoolFemaleGene ExpressionHumansMalaria, VivaxMalePlasmodium vivaxPolymerase Chain ReactionAntibodies, ProtozoanAntigens, Protozoan
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.